AAT-008（Cat No.:R067023）is a selective antagonist of the prostaglandin E2 receptor subtype EP4, which plays a key role in modulating immune responses, inflammation, and tumor progression. By blocking EP4 signaling, AAT-008 enhances antitumor immunity and inhibits immunosuppressive pathways within the tumor microenvironment. It is being investigated for use in cancer immunotherapy, particularly in combination with immune checkpoint inhibitors like anti-PD-1 antibodies. AAT-008 has shown promise in preclinical models by promoting cytotoxic T-cell activity and reducing tumor growth, making it a potential candidate for novel cancer treatment strategies.